A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer

Sadeleştirilmiş öğe sayfası
dc.contributor.authorKandhavelu, Jeyalakshmi
dc.contributor.authorSubramanian, Kumar
dc.contributor.authorNaidoo, Vivash
dc.contributor.authorSebastianelli, Giulia
dc.contributor.authorDoan, Phuong
dc.contributor.authorMani, Saravanan Konda
dc.contributor.authorYapislar, Hande
dc.contributor.authorHaciosmanoglu, Ebru
dc.contributor.authorArslan, Leman
dc.contributor.authorOzer, Samed
dc.contributor.authorThiyagarajan, Ramesh
dc.contributor.authorCandeias, Nuno R.
dc.contributor.authorPenny, Clement
dc.contributor.authorKandhavelu, Meenakshisundaram
dc.contributor.authorMurugesan, Akshaya
dc.date.accessioned2025-10-16T15:14:37Z
dc.date.issued2024
dc.identifier.doi10.1111/bph.16141
dc.identifier.otherWOS:001063394800001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6226
dc.publisherWILEY
dc.sourceBRITISH JOURNAL OF PHARMACOLOGY
dc.subjectalkylaminophenols
dc.subjectapoptosis
dc.subjectcolon cancer
dc.subjectEGFR inhibitor
dc.subjectoncogenesis
dc.titleA novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS